Immunoglobulin News and Research

RSS

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

New mathematical model predicts biological process that creates antibody diversity

Scientists at USC have created a mathematical model that explains and predicts the biological process that creates antibody diversity - the phenomenon that keeps us healthy by generating robust immune systems through hypermutation.

9 Oct 2013

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Professor Richard Pleass has won the Prix de l’Innovation 2013, also known as the Universal Biotech Innovation Prize 2013.

8 Oct 2013

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).

1 Oct 2013

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

...

30 Sep 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Japanese MHLW approves Hizentra for treatment of primary and secondary immunodeficiencies

CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.

27 Sep 2013

T. gondii antibodies implicated in mania

Infection with Toxoplasma gondii may confer an increased risk for mania, say researchers.

26 Sep 2013

Inflammation tracks mania course

Markers of inflammation are elevated in patients who are hospitalized for acute mania, a study shows.

24 Sep 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

Immune marker predicts transplant success, improves selection of bone marrow donors

The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children's Research Hospital. The findings appear in the September 16 online issue of the Journal of Clinical Oncology.

17 Sep 2013

Study finds similar antibody levels among 4 PCV13 immunization schedules

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

5 Sep 2013

Cangene Signs Up To $77M Contract Extension With CDC

...

3 Sep 2013

Cangene Inks Up To $77M Contract Extension With CDC

...

3 Sep 2013

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) provide the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research, which could one day lead to effective therapies against the virus, was published online ahead of print in the Journal of Virology.

25 Jul 2013

Initial polytherapy effectively improves prognosis of infantile spasms

Adrenocorticotropic hormone is recommended worldwide as an initial therapy for infantile spasms. However, infantile spasms in about 50% of children cannot be fully controlled by adrenocorticotropic hormone monotherapy, seizures recur in 33% of patients who initially respond to adrenocorticotropic hormone monotherapy, and side effects are relatively common during adrenocorticotropic hormone treatment.

22 Jul 2013

Weill Cornell reports new findings from IVIG Phase 3 trial in Alzheimer's disease at AAIC 2013

Weill Cornell Medical College neurologist Dr. Norman Relkin reported new findings today from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease at the Alzheimer's Association International Conference in Boston, Mass.

16 Jul 2013

Researchers identify risk factor for maternal antibody-related autism in subset of children

Researchers with the UC Davis MIND Institute have found that prenatal exposure to specific combinations of antibodies found only in mothers of children with autism leads to changes in the brain that adversely affect behavior and development.

10 Jul 2013

Vitamin D deficiency can increase asthma and allergy risk in obese children and teenagers

One reason why obese children and teenagers are more likely to have hard-to-control asthma and allergies may be vitamin D deficiency, a new study finds. Results of the study will be presented Tuesday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Anti-nicotine vaccination can increase accumulation of nicotine in the brain, say neuroscientists

Researchers have yet again been sent back to the drawing board in the development of the much-sought-after vaccination for smokers, which would hypothetically inhibit the action of nicotine and its pleasure-producing chemical response in the brain.

12 Jun 2013